awmsg logo



saxagliptin (Onglyza®)


Reference No. 1237

Publication date:
13/08/2012


Appraisal information

saxagliptin (Onglyza®) film-coated tablet


Company: AstraZeneca UK Ltd
BNF category: Endocrine system
NMG meeting date: 12/06/2012
AWMSG meeting date: 18/07/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2012
Ministerial ratification: 07/08/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Saxagliptin (Onglyza®) is recommended as an option for use within NHS Wales for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with insulin (with or without metformin) when this regimen alone with diet and exercise does not provide adequate glycaemic control.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download